Life-2023-02 Esophagogastric Variceal Bleeding

N/ARecruitingNCT06011980

Second Affiliated Hospital, School of Medicine, Zhejiang University33 enrolled

Overview

Study on the efficacy of the growth inhibitors after endoscopic treatment of acute esophagogastric variceal bleeding

Participants with acute esophagogastric variceal bleeding in 5 days and under stable status will be included in this study. All the patients will take CTP test to confirm the blood flow status of the portal vein before endoscopic treatment. After that they will be randomly divided into two groups: A. accept growth inhibitors after the endoscopic treatment for 5 days; B. no growth inhibitor will be applied after the treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Acute Esophageal Variceal Hemorrhage

Interventions

Growth InhibitorDRUG

growth inhibitors for 250-500μg/h, ivgtt. for 5 days

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * acute esophagogastric bleeding with hepatic cirhosis; * stable status (no active bleeding) Exclusion Criteria: * endoscopic test limitation; * previous acute esophagogastric bleeding treatment history; * ICU; * pregnant; * Immunity disabled;

Locations (1)

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Hanzhou, Zhejiang, China

RECRUITING

Outcomes

Primary Outcomes

rebleeding rate after the endoscopic treatment in Group A at 1 month

record the rebleeding incidence in this group A; (Rate A1= the number of rebleeding participants/the number of all the participants)

Time frame: 1 month after the endoscopic treatment

rebleeding rate after the endoscopic treatment in Group A at 3 months

record the rebleeding incidence in this group A; (Rate A2= the number of rebleeding participants/the number of all the participants)

Time frame: 3 months after the endoscopic treatment

rebleeding rate after the endoscopic treatment in Group A at 6 months

record the rebleeding incidence in this group A; (Rate A3= the number of rebleeding participants/the number of all the participants)

Time frame: 6 months after the endoscopic treatment

rebleeding rate after the endoscopic treatment in Group B at 1 month

record the rebleeding incidence in this group B; (Rate B1= the number of rebleeding participants/the number of all the participants)

Time frame: 1 month after the endoscopic treatment

rebleeding rate after the endoscopic treatment in Group B at 3 months

record the rebleeding incidence in this group B; (Rate B2= the number of rebleeding participants/the number of all the participants)

Time frame: 3 months after the endoscopic treatment

rebleeding rate after the endoscopic treatment in Group B at 6 months

record the rebleeding incidence in this group B; (Rate B3= the number of rebleeding participants/the number of all the participants)

Time frame: 6 months after the endoscopic treatment

Central Contacts

WEI WEI

CONTACT

15267175186 wwze@zju.edu.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.